Skip to content 
The rise of artificial intelligence technology Let medical care have more imagination AI+
Biomedicine. When the two “outlets” meet head-on What kind of sparks will collide In the field of biomedicine. There is a “3 10 law” about new drug research and development That is, it takes an average of 10 years and costs $1 billion And the success rate is only 10%Why is it so difficult? Taking cancer as an example, if the tumor is a lock, the target is the keyhole, and the drug is the key, in order to find the most suitable key, it takes a lot of energy and financial resources to screen.
In Nanjing Biomedical Valley
There is already a group of entrepreneurs and scientists
Through artificial intelligence technology
to develop innovative drugs and innovative medical devices
Cambrian Zhiyuan (Nanjing) Biomedical Technology Co., Ltd
Unlike the R&D team of traditional pharmaceutical companies, all of whom wear white coats to do experiments, some people in the R&D center of Cambrian Zhiyuan (Nanjing) Biomedical Technology Co., Ltd. are analyzing image data on computer screens. The team includes scientists from different fields such as brain science, photoelectric conversion, bioinformatics collection, and drug development, and everyone works together to find effective compounds and develop drugs for neurological diseases such as depression, schizophrenia, and Alzheimer’s disease, using the powerful image processing capabilities of artificial intelligence.
At present, Cambrian Zhiyuan has developed a set of research and development platform based on brain-like tissue chip-assisted artificial intelligence analysis, with completely independent intellectual property rights. “The platform’s leading edge is to visualize the brain’s working processes and the impact of drugs on brain function, thanks to the advancement of big data, AI models and GPU technology. Wang Nan, director of data analysis at Cambrian Zhiyuan, said.
Nanjing Chengshi Biomedical Technology Co., Ltd
mRNA vaccine is the most advanced technology system in the vaccine industry, and Nanjing Chengshi Biomedical Technology Co., Ltd. is AI-driven to develop mRNA vaccine products. At present, the company’s product system is divided into two categories, on the one hand, it is to develop therapeutic vaccines for human tumors, and on the other hand, it is to develop preventive vaccines for economic animals.
“In the past, the design of mRNA vaccines was mainly to screen and design antigens in the form of manual experiments. We use artificial intelligence to screen antigens, and the efficiency has been improved by more than 10 times. Fei Caiyi, vice president of Chengshi Biology, introduced that the company has set up an intelligent information team across multiple professional disciplines, and worked together with the biology team and clinical immunology team to greatly accelerate the design rhythm of the entire antigen and vaccine.
At present, Chengshi Biotech has established a completely independent technical system such as artificial intelligence antigen design system and mRNA design system, and on this basis, multiple R&D pipelines of mRNA therapeutic vaccines for acute leukemia, liver cancer, cranial glioma, breast cancer and osteosarcoma are being accelerated.
“In the field of economic animals, our R&D pipeline is advancing very quickly, and a number of products have been finalized and are expected to be launched next year. Fei Caiyi said that mRNA vaccines are likely to enable China’s veterinary vaccines to achieve “lane change and overtaking”.
Topway G-Xin Data Technology (Nanjing) Co., Ltd
The heart is one of the most important organs in the human body, it is composed of the left atrium, left ventricle, right atrium, and right ventricle. In the event of a heart valve problem, the most advanced treatment is a minimally invasive procedure for implantation of an artificial heart valve. In the Medicine Valley Park, Topway Heart Data Technology (Nanjing) Co., Ltd. has developed an artificial intelligence valve surgery planning system (CVPILOT) to “navigate” heart valve surgery.
“During interventional surgery, the prosthetic heart valve is placed in the right position on the heart through a delivery system. Wang Yuan, deputy general manager of Topway Heart Data Technology (Nanjing) Co., Ltd., introduced that judging the “right position” is a great test for doctors, and with CVPILOT, doctors only need to import the patient’s CT image into the system, they can see the patient’s 3D three-dimensional heart structure diagram, and obtain fully automatic auxiliary parameters, which can more intuitively, quickly and accurately select the area where the artificial heart valve is placed.
